Myo-inositol alone or with alpha-lactalbumin for women with polycystic ovary syndrome
Compares myo-inositol with and without alpha-lactalbumin in women with polycystic ovary syndrome.
Plain-language title generated from the registry record
Registry title: Myo-Inositol Alone Versus Myo-Inositol Plus Alpha-Lactalbumin in Women With Polycystic Ovary Syndrome
Key facts
- Where
- Chak Eighty-seven -Twelve Left, PakistanSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 18 to 35 with polycystic ovary syndrome (PCOS) who want to conceive. It compares myo-inositol alone with myo-inositol plus alpha-lactalbumin for 12 weeks.
- Age
- 18 to 35 years
- Sex
- Women only
- Disease stage
- Polycystic ovary syndrome diagnosed by Rotterdam criteria, for at least 6 months before enrollment.
- Earlier treatment
- No ovulation-induction agents, hormonal therapy, insulin sensitizers or anti-androgens in the previous 12 weeks.
Main reasons for not taking part
- Pre-existing diabetes, thyroid problems, hyperprolactinemia, Cushing syndrome or congenital adrenal hyperplasia
- Morbid obesity (BMI ≥40 kg/m²)
- Known cow milk protein allergy or severe gastrointestinal malabsorption
- Liver, kidney or heart and blood vessel impairment
- Tubal factor infertility, endometriosis, uterine structural problems or male factor infertility
Read by machine on 13 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 35 years old?
Source: NCT07629895, who can take part
Where in Pakistan
- Sadiq Abbasi Hospital/ Quaid-e-Azam Medical CollegeChak Eighty-seven -Twelve Left, PakistanContact: Kaleem A Dr, FCPSNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Quaid-e-Azam Medical College
- Trial code
- NCT07629895
- Record updated
- 9 June 2026
- Original description
Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting reproductive-aged women and is associated with menstrual irregularities, infertility, hyperandrogenism, obesity, and insulin resistance. Myo-inositol is commonly used as an insulin-sensitizing agent to improve reproductive and metabolic outcomes in women with PCOS. Alpha-lactalbumin may enhance the intestinal absorption and bioavailability of myo-inositol and potentially improve treatment response.Read full original descriptionShow less
Comparison of Efficacy of Myo-Inositol Alone With Myo-Inositol Plus Alpha-Lactalbumin on Reproductive and Metabolic Parameters in Polycystic Ovarian Syndrome
Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting reproductive-aged women and is associated with menstrual irregularities, infertility, hyperandrogenism, obesity, and insulin resistance. Myo-inositol is commonly used as an insulin-sensitizing agent to improve reproductive and metabolic outcomes in women with PCOS. Alpha-lactalbumin may enhance the intestinal absorption and bioavailability of myo-inositol and potentially improve treatment response.
This randomized controlled trial aims to compare the efficacy of myo-inositol alone versus myo-inositol plus alpha-lactalbumin in women with PCOS. Eighty-two eligible women will be randomized to receive either myo-inositol alone or myo-inositol combined with alpha-lactalbumin for 12 weeks. The study will evaluate reproductive outcomes including spontaneous conception, menstrual regularity, hirsutism, and hormonal parameters, as well as metabolic outcomes including body mass index and insulin resistance.
Inclusion: Female participants aged 18 to 35 years; Diagnosed with polycystic ovary syndrome according to Rotterdam criteria; Diagnosis of PCOS for at least 6 months before enrollment; Willing to conceive; Normal husband semen analysis.
Exclusion: Use of ovulation-induction agents, hormonal therapy, insulin sensitizers, or anti-androgens within the previous 12 weeks; Pre-existing diabetes mellitus; Cushing syndrome; Conditions causing ovulatory dysfunction and/or hyperandrogenism other than PCOS; Known cow milk protein allergy, hypersensitivity to study medications, or severe gastrointestinal malabsorption; Hepatic, renal, or cardiovascular impairment; Thyroid dysfunction; Hyperprolactinemia; Congenital adrenal hyperplasia; Androgen-secreting adrenal or ovarian tumors; Morbid obesity (BMI ≥40 kg/m²); Tubal factor infertility; Endometriosis; Structural uterine abnormality; Male factor infertility.